Rigel(RIGL) - 2025 Q4 - Annual Results

Financial Performance - Preliminary total revenue for Q4 2025 is approximately $69.8 million, a 21% increase from $57.6 million in Q4 2024[6] - Net product sales for Q4 2025 are expected to be $65.4 million, compared to $46.5 million in Q4 2024, representing a 40% growth[6] - Rigel anticipates full-year 2026 total revenue of approximately $275 to $290 million, including net product sales of $255 to $265 million[12] - The company reported cash, cash equivalents, and short-term investments of approximately $154.6 million as of December 31, 2025, up from $77.3 million in 2024[7] - Rigel's commercial portfolio is expected to achieve full-year net product sales of $232.0 million, reflecting a 60% growth compared to 2024[8] - TAVALISSE net product sales for Q4 2025 are expected to be $45.6 million, an increase from $31.0 million in Q4 2024[6] - GAVRETO net product sales for Q4 2025 are expected to be $10.2 million, compared to $8.1 million in Q4 2024[6] - Rigel's financial performance outlook for 2026 includes increased projections, although specific figures were not disclosed[22] Clinical Development - In the Phase 1b study of R289, red blood cell transfusion independence was achieved by 33% of evaluable patients receiving doses of at least 500 mg QD[5] - Rigel plans to complete enrollment in the dose expansion phase of the Phase 1b study and select the recommended Phase 2 dose in the second half of 2026[9] - The company expects to report positive net income for the full year 2026 while funding existing and new clinical development programs[12] - The company is actively enrolling participants in the R289 clinical study, which is crucial for future product development[22] - R289 remains an investigational compound and is not yet approved by the FDA[23] Commercialization Strategy - Rigel emphasizes the importance of clinical trial outcomes in predicting real-world results for its investigational compounds[22] - The company is focused on the commercialization of TAVALISSE, GAVRETO, and REZLIDHIA in both domestic and international markets[22] - Rigel anticipates continued growth in its commercial business and expects to present data from the R289 study[22] - Risks associated with the commercialization of its products include potential adverse decisions from regulatory authorities[22] - The company does not undertake any obligation to update forward-looking statements unless required by law[22]